Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Lead ZUMA-1 Researcher Highlights CAR T Cell Findings in NHL

April 12th 2017

Frederick L. Locke, MD, discusses the ZUMA-1 trial in non-Hodgkin lymphoma and the next steps going forward.

Dr. Salles on New Agents Being Investigated in Follicular Lymphoma

April 11th 2017

Gilles Salles MD, PhD, Centre Hospitalier Lyon-Sud, discusses new agents being investigated for patients with follicular lymphoma.

PI3K Inhibitor Copanlisib Active in Relapsed/Refractory Lymphoma

April 5th 2017

According to results from the phase II CHRONOS-1 trial, a majority of patients with relapsed or refractory indolent lymphoma responded to treatment with the PI3K dual-isoform inhibitor copanlisib.

CAR T Cell Functionality Correlates With Outcomes, Offering a Biomarker for Response

April 4th 2017

The flexibility of CAR T cells to perform multiple functions was associated with the level of clinical activity elicited for patients with advanced non-Hodgkin’s lymphoma, according to a retrospective analysis presented at the 2017 AACR Annual Meeting.

CAR T-Cell Response Rate Tops 80% in NHL Trial

April 4th 2017

Results of a phase II trial showed that more than 80% of patients with refractory non-Hodgkin lymphoma achieved objective responses to treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel.

Dr. Neelapu on Primary Results of the ZUMA-1 Trial in NHL

April 2nd 2017

Sattva S. Neelapu, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses primary results of the ZUMA-1 trial investigating axicabtagene ciloleucel (KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma.

FDA Submission Completed for Axicabtagene Ciloleucel in NHL

April 1st 2017

A biologics license application has been submitted for axicabtagene ciloleucel as a potential treatment for transplant ineligible patients with relapsed or refractory aggressive non-Hodgkin lymphoma.

Dr. Beaupre on Ibrutinib in Diffuse Large B-Cell Lymphoma

March 30th 2017

Darrin M. Beaupre, MD, head of Early Development and Immunotherapy at Pharmacyclics, discusses a trial of ibrutinib (Imbruvica) in diffuse large B-cell lymphoma (DLBCL).

Dr. Dogan on Updated WHO Classifications in DLBCL

March 30th 2017

Ahmet Dogan, MD, PhD, chief of Hematopathology Service, Departments of Pathology and Laboratory Medicine at Memorial Sloan Kettering Cancer Center, discusses the updated World Health Organization (WHO) classification and how it impacts treatment decisions for patients with diffuse large B-cell lymphoma (DLBCL).

Dr. Fowler on Different Responses to Therapy for Follicular Lymphoma

March 30th 2017

Nathan Fowler, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the differences in response to the same therapy for patients with follicular lymphoma.

New Standards Are Emerging for Follicular Lymphoma and CLL

March 20th 2017

Controlling indolent non-Hodgkin lymphoma remains a priority as it has the potential to transform to aggressive or high-grade lymphoma.

Expert Discusses JCAR017 CAR T-Cell Therapy in Non-Hodgkin Lymphoma

March 6th 2017

Leo I. Gordon MD, discusses results from the TRANSCEND trial and the next steps with chimeric antigen receptor T-cell therapy in non-Hodgkin lymphoma.

Juno Accelerates Development of JCAR017, Halts JCAR015

March 2nd 2017

Juno therapeutics has shifted its focus toward the development of JCAR017 for relapsed/refractory diffuse large B-cell lymphoma after a series of toxicity-related setbacks culminated in the need to halt the development of JCAR015.

Ibrutinib Benefit in Waldenstrom Macroglobulinemia Sustained With Latest Data

March 2nd 2017

Single-agent ibrutinib induced a response rate of 90% at a median follow-up of 18.1 months in rituximab-refractory patients with Waldenstrom macroglobulinemia, according to results from an open-label substudy of the ongoing phase III iNNOVATE trial published in The Lancet Oncology.

Dr. Salles on Frontline Management of Follicular Lymphoma

March 1st 2017

Gilles Salles, MD, PhD, Centre Hospitalier Lyon-Sud, discusses frontline treatment management for patients with follicular lymphoma.

Dr. Fowler on FLIPI Scoring System in Follicular Lymphoma

March 1st 2017

Nathan Fowler, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the FLIPI scoring system in follicular lymphoma.

Axicabtagene Ciloleucel Shows High CR Rates in Primary Analysis of ZUMA-1 Study

February 28th 2017

Treatment with axicabtagene ciloleucel demonstrated an objective response rate of 82% and a complete response rate of 54% for patients with aggressive non-Hodgkin lymphoma.

Axicabtagene Ciloleucel Shows Response Rate of 76% in Aggressive Lymphoma

February 27th 2017

Axicabtagene ciloleucel had an objective response rate of 76% and a complete response rate of 47% in patients with aggressive non-Hodgkin lymphoma followed for at least 1 month.

Researchers Examine Acquired Mutations Linked to Ibrutinib Resistance in CLL

February 25th 2017

Researchers hope the acquired ibrutinib resistance mutations BTK and PLCG2 can be used as biomarkers for early intervention opportunities in patients with chronic lymphocytic leukemia.

Dr. Salles on Improving Immune Respone in Follicular Lymphoma

February 15th 2017

Gilles A. Salles, MD, PhD, Centre Hospitalier Lyon-Sud, discusses improving immune response in follicular lymphoma.